13. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A (2007) Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 41(9): 1411–1426. 10.1345/aph.1H658. 14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol 62(10): e1–34. 10.1016/j.jclinepi.2009.06.006. 15. von Elm E, Poglia G, Walder B, Tramer MR (2004) Different patterns of duplicate publication: An analysis of articles used in systematic reviews. JAMA 291(8): 974–980. 10.1001/jama.291.8.974. 16. World Health Organization (1972) International drug monitoring: The role of national centres. Technical Report Series 498. 17. Edwards IR, Aronson JK (2000) Adverse drug reactions: Definitions, diagnosis, and management. Lancet 356(9237): 1255–1259. 10.1016/S0140-6736(00)02799-9. 18. Brvar M, Fokter N, Bunc M, Mozina M (2009) The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharmacol 9: 8. 10.1186/1472- 6904-9-8. 19. Rawlins MD, Thompson JW (1977) Pathogenesis of adverse drug reactions. In: Davies DM, ed (1977) Textbook of adverse drug reactions. Oxford: University Press. 44 p. 20. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 61(4): 344–349. 10.1016/j.jclinepi.2007.11.008. 21. Sanderson S, Tatt ID, Higgins JP (2007) Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: A systematic review and annotated bibliography. Int J Epidemiol 36(3): 666–676. 10.1093/ ije/dym018. 22. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3): 177–188. 23. Pearson TF, Pittman DG, Longley JM, Grapes ZT, Vigliotti DJ, et al. (1994) Factors associated with preventable adverse drug reactions. Am J Hosp Pharm 51(18): 2268–2272. 24. Courtman BJ, Stallings SB (1995) Characterization of drug-related problems in elderly patients on admission to a medical ward. Can J Hosp Pharm 48(3): 161–166. 25. Dartnell JG, Anderson RP, Chohan V, Galbraith KJ, Lyon ME, et al. (1996) Hospitalisation for adverse events related to drug therapy: Incidence, avoidability and costs. Med J Aust 164(11): 659–662. 26. Tafreshi MJ, Melby MJ, Kaback KR, Nord TC (1999) Medication-related visits to the emergency department: A prospective study. Ann Pharmacother 33(12): 1252–1257. 27. Chan M, Nicklason F, Vial JH (2001) Adverse drug events as a cause of hospital admission in the elderly. Intern Med J 31(4): 199–205. 28. Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc JL, et al. (2002) Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: A study in a french emergency department. Drug Saf 25(14): 1035–1044. 29. Dormann H, Criegee-Rieck M, Neubert A, Egger T, Geise A, et al. (2003) Lack of awareness of community-acquired adverse drug reactions upon hospital admission : Dimensions and consequences of a dilemma. Drug Saf 26(5): 353–362. 30. Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Troger M, et al. (2004) Readmissions and adverse drug reactions in internal medicine: The economic impact. J Intern Med 255(6): 653–663. 10.1111/j.1365-2796.2004.01326.x. 31. Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. (2004) Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 329(7456): 15–19. 10.1136/bmj.329.7456.15. 32. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, et al. (2007) Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: A prospective study. BMC Clin Pharmacol 7: 8. 10.1186/1472-6904-7-8. 33. Alexopoulou A, Dourakis SP, Mantzoukis D, Pitsariotis T, Kandyli A, et al. (2008) Adverse drug reactions as a cause of hospital admissions: A 6-month experience in a single center in greece. Eur J Intern Med 19(7): 505–510. 10.1016/j.ejim.2007.06.030. 34. Franceschi M, Scarcelli C, Niro V, Seripa D, Pazienza AM, et al. (2008) Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf 31(6): 545–556. Preventable Adverse Drug Reactions – Meta-Analysis 35. Hopf Y, Watson M, Williams D (2008) Adverse-drug-reaction related admissions to a hospital in scotland. Pharm World Sci 30(6): 854–862. 10.1007/s11096- 008-9240-5. 36. Ruiz B, Garcia M, Aguirre U, Aguirre C (2008) Factors predicting hospital readmissions related to adverse drug reactions. Eur J Clin Pharmacol 64(7): 715–722. 10.1007/s00228-008-0473-y. 37. van der Hooft CS, Dieleman JP, Siemes C, Aarnoudse AJ, Verhamme KM, et al. (2008) Adverse drug reaction-related hospitalisations: A population-based cohort study. Pharmacoepidemiol Drug Saf 17(4): 365–371. 10.1002/pds.1565. 38. Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, et al. (2008) Incidence, severity and preventability of medication-related visits to the emergency department: A prospective study. CMAJ 178(12): 1563–1569. 10.1503/cmaj.071594. 39. Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, et al. (1990) Drug related hospital admissions: The role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 228(2): 83–90. 40. Schumock GT, Seeger JD, Kong SX (1995) Control charts to monitor rates of adverse drug reactions. Hosp Pharm 30(12): 1088, 1091-2, 1095-6. 41. Gholami K, Shalviri G (1999) Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 33(2): 236–240. 42. Baniasadi S, Fahimi F, Shalviri G (2008) Developing an adverse drug reaction reporting system at a teaching hospital. Basic Clin Pharmacol Toxicol 102(4): 408–411. 10.1111/j.1742-7843.2008.00217.x. 43. Davies EC, Green CF, Mottram DR, Pirmohamed M (2006) Adverse drug reactions in hospital in-patients: A pilot study. J Clin Pharm Ther 31(4): 335–341. 10.1111/j.1365-2710.2006.00744.x. 44. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, et al. (2009) Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. PLoS One 4(2): e4439. 10.1371/journal.pone.0004439. 45. Pourseyed S, Fattahi F, Pourpak Z, Gholami K, Shariatpanahi SS, et al. (2009) Adverse drug reactions in patients in an iranian department of internal medicine. Pharmacoepidemiol Drug Saf 18(2): 104–110. 10.1002/pds.1663. 46. Farcas A, Sinpetrean A, Mogosan C, Palage M, Vostinaru O, et al. (2010) Adverse drug reactions detected by stimulated spontaneous reporting in an internal medicine department in romania. Eur J Intern Med 21(5): 453–457. 10.1016/j.ejim.2010.05.014. 47. Levy M, Lipshitz M, Eliakim M (1979) Hospital admissions due to adverse drug reactions. Am J Med Sci 277(1): 49–56. 48. Ramsay LE, Freestone S, Silas JH (1982) Drug-related acute medical admissions. Hum Toxicol 1(4): 379–386. 49. Hallas J, Gram LF, Grodum E, Damsbo N, Brosen K, et al. (1992) Drug related admissions to medical wards: A population based survey. Br J Clin Pharmacol 33(1): 61–68. 50. Hallas J, Harvald B, Worm J, Beck-Nielsen J, Gram LF, et al. (1993) Drug related hospital admissions. Results from an intervention program. Eur J Clin Pharmacol 45(3): 199–203. 51. Ponge T, Cottin S, Fruneau P, Ponge A, Van Wassenhove L, et al. (1989) Iatrogenic disease. prospective study, relation to drug consumption [in French]. Therapie 44(1): 63–66. 52. Stelfox HT, Palmisani S, Scurlock C, Orav EJ, Bates DW (2006) The "to err is human" report and the patient safety literature. Qual Saf Health Care 15(3): 174–178. 10.1136/qshc.2006.017947. 53. Royal S, Smeaton L, Avery AJ, Hurwitz B, Sheikh A (2006) Interventions in primary care to reduce medication related adverse events and hospital admissions: Systematic review and meta-analysis. Qual Saf Health Care 15(1): 23–31. 10.1136/qshc.2004.012153. 54. Leape LL (1994) Error in medicine. JAMA 272(23): 1851–1857. 55. Ferner RE, Aronson JK (2010) Preventability of drug-related harms - part I: A systematic review. Drug Saf 33(11): 985–994. 10.2165/11538270-000000000- 00000. 56. Hakkarainen KM, Andersson Sundell K, Petzold M, Ha¨gg S (2012) Methods for assessing the preventability of adverse drug events - A systematic review. Drug Saf 35(2): 105–126. 10.2165/11596570-000000000-00000. 57. Imbs JL, Pletan Y, Spriet A (1998) Assessment of preventable iatrogenic drug therapy: Methodology. round table no 2 at giens XIII [in French]. Therapie 53(4): 365–370. 58. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, et al. (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289(9): 1107–1116. PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33236